These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27092864)

  • 1. Successful treatment of multiple vemurafenib-induced keratoacanthomas by topical application of imiquimod cream: Confirmation of clinical clearance by dermoscopy.
    Rhee do Y; Won KH; Lee YJ; Won CH; Chang SE; Lee MW
    J Dermatolog Treat; 2016 Oct; 27(5):448-9. PubMed ID: 27092864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
    Alloo A; Garibyan L; LeBoeuf N; Lin G; Werchniak A; Hodi FS; Flaherty KT; Lawrence DP; Lin JY
    Arch Dermatol; 2012 Mar; 148(3):363-6. PubMed ID: 22431777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Sinha R; Larkin J; Gore M; Fearfield L
    Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous adverse events during vemurafenib therapy.
    Chandrakumar SF; Yeung J
    J Cutan Med Surg; 2014; 18(4):223-8. PubMed ID: 25008438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
    Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
    Sibaud V; Lamant L; Maisongrosse V; Delord JP
    Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
    Chu EY; Wanat KA; Miller CJ; Amaravadi RK; Fecher LA; Brose MS; McGettigan S; Giles LR; Schuchter LM; Seykora JT; Rosenbach M
    J Am Acad Dermatol; 2012 Dec; 67(6):1265-72. PubMed ID: 22609219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.
    Johnson DB; Wallender EK; Cohen DN; Likhari SS; Zwerner JP; Powers JG; Shinn L; Kelley MC; Joseph RW; Sosman JA
    Cancer Immunol Res; 2013 Dec; 1(6):373-7. PubMed ID: 24490176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced expression of the ATP2A2 gene in vemurafenib-induced keratoacanthoma-like papules in a melanoma patient.
    Wakimoto H; Harada K; Arai T; Maeda T; Irisawa R; Tsuboi R
    Int J Dermatol; 2017 Feb; 56(2):e33-e35. PubMed ID: 27805257
    [No Abstract]   [Full Text] [Related]  

  • 10. Dermatological approach to vemurafenib skin toxicity: a single centre experience.
    Fava P; Marra E; Astrua C; Brizio M; Cavaliere G; Quaglino P; Fierro MT; Savoia P
    G Ital Dermatol Venereol; 2016 Feb; 151(1):25-31. PubMed ID: 25296968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
    Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
    Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream.
    Di Lernia V; Ricci C; Albertini G
    J Eur Acad Dermatol Venereol; 2004 Sep; 18(5):626-9. PubMed ID: 15324413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil.
    LaPresto L; Cranmer L; Morrison L; Erickson CP; Curiel-Lewandrowski C
    JAMA Dermatol; 2013 Mar; 149(3):279-81. PubMed ID: 23552479
    [No Abstract]   [Full Text] [Related]  

  • 14. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
    Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H
    Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
    Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
    J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of vemurafenib-induced keratosis pilaris-like eruption.
    Wang CM; Fleming KF; Hsu S
    Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clearance of BRAF inhibitor-associated keratoacanthomas by systemic retinoids.
    Sachse MM; Wagner G
    Br J Dermatol; 2014 Feb; 170(2):475-7. PubMed ID: 24117280
    [No Abstract]   [Full Text] [Related]  

  • 18. Vemurafenib-induced eccrine squamous syringometaplasia.
    Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
    Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Outcomes of Melanoma In Situ Treated With Topical 5% Imiquimod Cream: A Retrospective Review.
    Park AJ; Paul J; Chapman MS; Samie FH
    Dermatol Surg; 2017 Aug; 43(8):1017-1022. PubMed ID: 28328708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream.
    Ray CM; Kluk M; Grin CM; Grant-Kels JM
    Int J Dermatol; 2005 May; 44(5):428-34. PubMed ID: 15869545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.